Clinical Spotlight
Hormone receptor positive (HR+) breast cancer constitutes 75% of all breast cancers.1 Single endocrine therapy (ET) was the standard treatment for patients with HR+/human epidermal growth factor receptor 2 negative (HER2-) advanced disease, but primary and secondary resistance have resulted in a poor prognosis for many patients.2 CDK4/6 inhibitors plus ET are now recommended in HR+/HER2- advanced breast cancer.3 However, many patients still receive chemotherapy or single-agent ET as first-line treatment.4,5 With no biomarkers to reliably guide CDK4/6 inhibitor use, there is no consensus on optimal treatment selection and sequencing for different patient subgroups. Emerging data are showing that disease and patient characteristics may impact on the optimal treatment strategy.6 Effective adverse event (AE) management is essential to ensure optimal treatment with CDK4/6 inhibitors, but AE management strategies remain a key unmet need in many clinical settings.7 Ongoing clinical trials with CDK4/6 inhibitors are exploring their use earlier in the disease continuum.8
Module 1: How do we optimize patient selection, treatment sequencing and AE management for HR+/HER2- advanced breast cancer therapy in the era of CDK4/6 inhibition?
Professor Nadia Harbeck and Professor Mario Campone provide insights into the latest data on treatment selection in HR+/HER2- advanced breast cancer. Patient and disease characteristics, factors that influence treatment sequencing and the AE profiles of CDK4/6 inhibitors and their management are discussed.
Start Module

Module 2: Clinical challenges in action: what would you do in our interactive case scenarios?
Professor Stephen Johnston presents interactive case studies of patients with advanced breast cancer and considers factors influencing treatment selection and tailoring to optimize outcomes.
Start Module

Module 3: Current challenges with CDK4/6 inhibitors in advanced breast cancer and moving forwards in early breast cancer
Professor Stephen Johnston leads a faculty discussion of questions from the audience concerning CDK4/6 inhibitors in advanced breast cancer, and a review of current studies investigating CDK4/6 inhibitors in early breast cancer.
Start Module
